Shanghai Allist Pharmaceuticals Co., Ltd. (SHA:688578)
China · Delayed Price · Currency is CNY 95.68
-1.22 (-1.26%)
Feb 13, 2026, 3:00 PM CST
SHA:688578 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 4,757 | 3,558 | 2,018 | 790.94 | 530.08 | 0.55 |
Other Revenue | 0.04 | 0.04 | 0.06 | 0.06 | 0.02 | 0.02 |
| 4,757 | 3,558 | 2,018 | 791 | 530.09 | 0.56 | |
Revenue Growth (YoY) | 48.49% | 76.29% | 155.14% | 49.22% | 94409.97% | -10.93% |
Cost of Revenue | 182.42 | 168.99 | 110.02 | 47.11 | 29.95 | 0.16 |
Gross Profit | 4,575 | 3,389 | 1,908 | 743.9 | 500.14 | 0.4 |
Selling, General & Admin | 2,072 | 1,578 | 1,052 | 524.11 | 366.44 | 185.12 |
Research & Development | 394.14 | 288.99 | 280.92 | 175.71 | 200.61 | 175.42 |
Other Operating Expenses | 108.29 | 46.81 | 26.6 | 5.11 | 2.79 | 1.64 |
Operating Expenses | 2,575 | 1,914 | 1,360 | 705.26 | 569.95 | 362.16 |
Operating Income | 2,000 | 1,475 | 548.3 | 38.64 | -69.81 | -361.76 |
Interest Expense | -0.14 | -0.07 | -0.16 | -0.33 | -0.61 | -1.14 |
Interest & Investment Income | 64.05 | 67.04 | 60.19 | 33.06 | 30.06 | 21.4 |
Currency Exchange Gain (Loss) | 1.9 | 1.9 | 4.35 | 17.17 | -3.38 | -0.35 |
Other Non Operating Income (Expenses) | 10.35 | 0.17 | 0.99 | -1.06 | -0.43 | -0.1 |
EBT Excluding Unusual Items | 2,077 | 1,544 | 613.68 | 87.47 | -44.16 | -341.96 |
Gain (Loss) on Sale of Investments | 43.17 | 28.89 | 22.67 | 32.36 | 48.13 | 8.3 |
Gain (Loss) on Sale of Assets | 0.02 | -0.01 | -0.02 | -1.68 | -0.57 | - |
Asset Writedown | - | - | - | - | - | -0.02 |
Other Unusual Items | 196.44 | 45.66 | 19.89 | 7.85 | 14.88 | 23.16 |
Pretax Income | 2,316 | 1,619 | 656.22 | 126 | 18.27 | -310.52 |
Income Tax Expense | 333.47 | 188.67 | 12.05 | -4.52 | - | - |
Net Income | 1,983 | 1,430 | 644.17 | 130.52 | 18.27 | -310.52 |
Net Income to Common | 1,983 | 1,430 | 644.17 | 130.52 | 18.27 | -310.52 |
Net Income Growth | 52.90% | 121.97% | 393.54% | 614.22% | - | - |
Shares Outstanding (Basic) | 449 | 450 | 450 | 450 | 457 | 370 |
Shares Outstanding (Diluted) | 449 | 450 | 450 | 450 | 457 | 370 |
Shares Change (YoY) | -0.14% | -0.18% | 0.09% | -1.49% | 23.59% | 2.30% |
EPS (Basic) | 4.41 | 3.18 | 1.43 | 0.29 | 0.04 | -0.84 |
EPS (Diluted) | 4.41 | 3.18 | 1.43 | 0.29 | 0.04 | -0.84 |
EPS Growth | 53.11% | 122.38% | 393.10% | 625.00% | - | - |
Free Cash Flow | 1,881 | 1,296 | 606.77 | -52.21 | -162.95 | -285.2 |
Free Cash Flow Per Share | 4.19 | 2.88 | 1.35 | -0.12 | -0.36 | -0.77 |
Dividend Per Share | 0.800 | 0.650 | 0.400 | - | - | - |
Dividend Growth | 23.08% | 62.50% | - | - | - | - |
Gross Margin | 96.17% | 95.25% | 94.55% | 94.05% | 94.35% | 71.17% |
Operating Margin | 42.05% | 41.45% | 27.17% | 4.88% | -13.17% | -64498.21% |
Profit Margin | 41.68% | 40.19% | 31.92% | 16.50% | 3.45% | -55361.45% |
Free Cash Flow Margin | 39.54% | 36.42% | 30.06% | -6.60% | -30.74% | -50847.96% |
EBITDA | 2,036 | 1,511 | 585.25 | 58.8 | -56 | -349.9 |
EBITDA Margin | 42.80% | 42.48% | 29.00% | 7.43% | -10.56% | - |
D&A For EBITDA | 35.85 | 36.32 | 36.94 | 20.16 | 13.81 | 11.86 |
EBIT | 2,000 | 1,475 | 548.3 | 38.64 | -69.81 | -361.76 |
EBIT Margin | 42.05% | 41.45% | 27.17% | 4.88% | -13.17% | - |
Effective Tax Rate | 14.40% | 11.66% | 1.84% | - | - | - |
Revenue as Reported | 4,757 | 3,558 | 2,018 | 791 | 530.09 | 0.56 |
Advertising Expenses | - | 863.51 | 552.06 | 201.38 | 22.44 | 0.47 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.